Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

453 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study.
Marasco V, Piciocchi A, Candoni A, Pagano L, Guidetti A, Musto P, Bruna R, Bocchia M, Visentin A, Turrini M, Tucci A, Pilerci S, Fianchi L, Salvini M, Galimberti S, Coviello E, Selleri C, Luppi M, Crea E, Fazi P, Passamonti F, Corradini P. Marasco V, et al. Among authors: tucci a. Br J Haematol. 2022 Oct;199(1):54-60. doi: 10.1111/bjh.18385. Epub 2022 Jul 30. Br J Haematol. 2022. PMID: 35906881 Free PMC article.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Galimberti S, et al. Among authors: tucci a. Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316810 Free article.
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial.
Bruna R, Benedetti F, Boccomini C, Patti C, Barbui AM, Pulsoni A, Musso M, Liberati AM, Gini G, Castellino C, Rossini F, Ciceri F, Rota-Scalabrini D, Stelitano C, Di Raimondo F, Tucci A, Devizzi L, Zoli V, Zallio F, Narni F, Dondi A, Parvis G, Semenzato G, Lanza F, Perrone T, Angrilli F, Billio A, Gueli A, Mantoan B, Rambaldi A, Gianni AM, Corradini P, Passera R, Ladetto M, Tarella C. Bruna R, et al. Among authors: tucci a. Haematologica. 2019 Nov;104(11):2241-2248. doi: 10.3324/haematol.2018.209932. Epub 2019 Apr 11. Haematologica. 2019. PMID: 31666344 Free PMC article. Clinical Trial.
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G. Cattaneo C, et al. Among authors: tucci a. Cancer. 2020 Dec 1;126(23):5069-5076. doi: 10.1002/cncr.33160. Epub 2020 Sep 10. Cancer. 2020. PMID: 32910456 Free article.
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C, Ladetto M, Rigacci L, Puccini B, Rattotti S, Volpetti S, Ferrero S, Chiarenza A, Freilone R, Novo M, Corradini P, Nassi L, Rusconi C, Stelitano C, Bolis S, Marina Liberati A, Tucci A, Baldini L, Balzarotti M, Evangelista A, Ciccone G, Vitolo U. Boccomini C, et al. Among authors: tucci a. Br J Haematol. 2021 Apr;193(2):280-289. doi: 10.1111/bjh.17283. Epub 2021 Jan 21. Br J Haematol. 2021. PMID: 33476434 Clinical Trial.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, Balzarotti M, Carniti C, Monfrini C, Chiappella A, Cabras A, Facchetti F, Pennisi M, Rahal D, Monti V, Devizzi L, Miceli R, Cocito F, Farina L, Ricci F, Rossi G, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: tucci a. Haematologica. 2022 May 1;107(5):1153-1162. doi: 10.3324/haematol.2021.278638. Haematologica. 2022. PMID: 34289655 Free PMC article.
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab.
Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A, Chiorini JA, Su HC, Cohen JI, Burbelo PD, Rossi G, Notarangelo LD. Cattaneo C, et al. Among authors: tucci a. Blood Cancer J. 2021 Sep 14;11(9):151. doi: 10.1038/s41408-021-00546-9. Blood Cancer J. 2021. PMID: 34521813 Free PMC article.
Genetic and phenotypic attributes of splenic marginal zone lymphoma.
Bonfiglio F, Bruscaggin A, Guidetti F, Terzi di Bergamo L, Faderl M, Spina V, Condoluci A, Bonomini L, Forestieri G, Koch R, Piffaretti D, Pini K, Pirosa MC, Cittone MG, Arribas A, Lucioni M, Ghilardi G, Wu W, Arcaini L, Baptista MJ, Bastidas G, Bea S, Boldorini R, Broccoli A, Buehler MM, Canzonieri V, Cascione L, Ceriani L, Cogliatti S, Corradini P, Derenzini E, Devizzi L, Dietrich S, Elia AR, Facchetti F, Gaidano G, Garcia JF, Gerber B, Ghia P, Gomes da Silva M, Gritti G, Guidetti A, Hitz F, Inghirami G, Ladetto M, Lopez-Guillermo A, Lucchini E, Maiorana A, Marasca R, Matutes E, Meignin V, Merli M, Moccia A, Mollejo M, Montalban C, Novak U, Oscier DG, Passamonti F, Piazza F, Pizzolitto S, Rambaldi A, Sabattini E, Salles G, Santambrogio E, Scarfò L, Stathis A, Stüssi G, Geyer JT, Tapia G, Tarella C, Thieblemont C, Tousseyn T, Tucci A, Vanini G, Visco C, Vitolo U, Walewska R, Zaja F, Zenz T, Zinzani PL, Khiabanian H, Calcinotto A, Bertoni F, Bhagat G, Campo E, De Leval L, Dirnhofer S, Pileri SA, Piris MA, Traverse-Glehen A, Tzankov A, Paulli M, Ponzoni M, Mazzucchelli L, Cavalli F, Zucca E, Rossi D. Bonfiglio F, et al. Among authors: tucci a. Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood.2021012386. Blood. 2022. PMID: 34653238 Free article.
The safety and clinical effectiveness of rapid infusion with CT-P10 in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia: A retrospective non-interventional post-authorization safety study in Europe.
Bishton M, Marshall S, Harchowal J, Salles G, Golfier C, Tucci A, Fernández AR, Sanchez Blanco JJ, Bocchia M, Kim S, Lee YN, Zinzani PL. Bishton M, et al. Among authors: tucci a. Hematol Oncol. 2022 Aug;40(3):370-380. doi: 10.1002/hon.2978. Epub 2022 Mar 17. Hematol Oncol. 2022. PMID: 35168291 Free PMC article.
453 results